Eli Lilly and Company (NYSE:LLY) is included in the list of the best performing S&P 500 stocks in the last five years. As of ...

Eli Lilly's fourth quarter performance was defined by accelerating demand for its obesity and diabetes medicines, as well as ...

Despite their huge popularity, GLP-1 injury lawsuits citing the drugs as a cause for a host of severe GI issues and even ...

Eli Lilly will shell out $2.4 billion to acquire genetic medicine developer Orna Therapeutics and has committed up to $8.85 billion to launch a seventh collaboration with Innovent Biologics. Both ...

The S&P 500 was on track for double-digit earnings growth, with more than half of companies having reported Q4 results so far ...

Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company ...

Detailed price information for Royalty Pharma Plc Cl A (RPRX-Q) from The Globe and Mail including charting and trades.

Should investors be buying healthcare shares this year? The post 3 reasons to target global healthcare in 2026 -expert appeared first on The Motley Fool Australia.

Pharmaceutical company Organon (NYSE:OGN) will be announcing earnings results this Thursday morning. Here’s what you need to know. Organon beat analysts’ revenue expectations by 2% last quarter, ...

Myers' upcoming $30B patent cliff as the Growth portfolio lost significant potential. Read why BMY stock is downgraded to Hold.